Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization

Autor:	Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	SCLC small cell lung cancer lurbinectedin chemotherapy-free interval second line real world evidence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Current Oncology, Vol 29, Iss 12, Pp 9744-9752 (2022)
Druh dokumentu:	article
ISSN:	1718-7729 1198-0052
DOI:	10.3390/curroncol29120765
Popis:	Background: In the ATLANTIS study, second-line lurbinectedin/doxorubicin did not improve overall survival (OS), however patients with a chemotherapy-free interval (CTFI) of ≥180 days had an improved progression free survival (PFS). The objective of this retrospective study was to identify the proportion of real-world small cell lung cancer (SCLC) patients who are suitable for lurbinectedin-based therapy based on these criteria. Methods: A retrospective study of all SCLC referred to BC Cancer between 2012 and 2017 was conducted. Patient demographics, staging, treatment, and survival data were collected retrospectively. Baseline characteristics were compared using descriptive statistics. OS was calculated using Kaplan–Meier curves. Statistically significant p-value was
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/bbaa81df53e848dd85a20e423523f98f Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.